Advancing cryptococcal treatment: The role of nanoparticles in mitigating antifungal resistance

•Cryptococcal infections contribute significantly to global morbidity and mortality, especially in immunocompromised individuals.•Increasing antifungal resistance highlights the need for advanced treatment strategies.•Nanoparticles like Ag, Se, and bee venom-loaded chitosan NPs show promising antifungal activity.•Liposomes, dendrimers, and nanostructured lipid carriers offer potential to enhance efficacy and reduce side effects. Cryptococcus, a ubiquitous and formidable fungal pathogen, contributes to a substantial global disease burden, with nearly 250,000 cases and 181,000 fatalities attributed to cryptococcal meningitis annually worldwide. The invasive nature of Cryptococcus presents significant challenges in treatment and management, as it mostly affects vulnerable populations, including HIV patients, organ transplant recipients, pregnant women, and elderly individuals. Moreover, these difficulties are exacerbated by the development of antifungal resistance, which emphasizes the need for efficient control measures. In this context, research efforts focusing on infection control and novel therapeutic strategies become paramount. Nanoparticle-based therapies emerge as a solution, offering advanced antifungal properties and improved efficacy. Developing effective treatment options requires understanding the complex landscape of cryptococcal infections and the innovative potential of nanoparticle-based therapies. This review highlights the urgent need for novel strategies to combat the growing threat posed by antifungal resistance while offering insights into the intricate realm of cryptococcal infections, particularly focusing on the promising role of nanoparticle-based therapies. [Display omitted]